Supple Table 1. Correlations between changes in HbA1c and those in clinical variables from baseline to 24 weeks after treatment with dapagliflozin in 33 people with type 2 diabetes and NAFLD

	Changes in HbA1c (%)	
Variable	r	P value
Changes in body weight (Kg)	-0.3274	0.0674
Changes in BMI	-0.3029	0.0977
Changes in VFA (cm^2)	-0.08627	0.6445
Changes in total fat mass (kg)	-0.01607	0.9328
Changes in total body water (kg)	-0.4568	0.0112
Changes in FPG (mmol/l)	0.3472	0.0602
Changes in LDL cholesterol (mmol/l)	0.2268	0.2198
Changes in Triglyceride (mmol/l)	-0.1751	0.3461
Changes in HDL-cholesterol (mmol/l)	-0.1732	0.3514
Changes in ALT (U/L)	0.08692	0.6420
Changes in GGT (U/L)	0.03607	0.8473
Changes in uric acid (μmol/l)	-0.2052	0.2682
Changes in eGFR (ml/min1.73m^2)	0.3638	0.0407
Changes in hematocrit (%)	-0.01487	0.9367
Changes in HMW adiponectin (μg/ml)	-0.3927	0.0289

Changes in hs-CRP (μg/ml)	0.131	0.4823
Changes in type 4 collagen 7S (ng/ml)	0.4072	0.0230
Changes in CAP (dB/m)	0.4288	0.0203

BMI, body mass index; WC, waist circumference; VFA, visceral fat area; FPG, fasting plasma glucose; LDL, low-density lipoprotein; HDL, high-density lipoprotein; RLP, remnant like lipoprotein; AST, aspartate aminotransferase; ALT, alanine transaminase; GGT, γ-glutamyltranspeptidase ;eGFR, estimated glomerular filtration rate; hs-CRP, high sensitivity C-reactive protein; HMW, high-molecular weight; CAP, controlled attenuation parameter